S. Quayle

发表

Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

M. Selig, N. Raje, L. Boise, 2015, British journal of haematology.

Emerging insights into the molecular and cellular basis of glioblastoma.

Lynda Chin, William C Hahn, Gavin P Dunn, 2012, Genes & development.

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

David M. Woods, I. Dolgalev, A. Laino, 2019, Journal of Immunotherapy for Cancer.

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers

F. Bertucci, D. Birnbaum, W. Woodward, 2015, Breast Cancer Research.

Peptide-HLA-based immunotherapeutics platforms for direct modulation of antigen-specific T cells

S. Almo, P. Kiener, J. Ross, 2021, Scientific Reports.

HDAC1,2 inhibition impairs EZH2- and BBAP- mediated DNA repair to overcome chemoresistance in EZH2 gain-of-function mutant diffuse large B-cell lymphoma

B. Cairns, J. Shearstone, J. Tyler, 2014, Oncotarget.

Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor

Simon S. Jones, Brian J North, S. Quayle, 2017, PloS one.

HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model

J. Pinilla-Ibarz, Simon S. Jones, S. Quayle, 2020, Frontiers in Immunology.

Androgen receptor decoy molecules block the growth of prostate cancer

M. Sadar, Jun Wang, S. Quayle, 2007, Proceedings of the National Academy of Sciences.

IN VITRO AND IN VIVO INTERACTIONS BETWEEN THE HDAC6 INHIBITOR RICOLINOSTAT (ACY1215) AND THE IRREVERSIBLE PROTEASOME INHIBITOR CARFILZOMIB IN NON-HODGKIN’S LYMPHOMA CELLS

S. Grant, S. Quayle, G. Dasmahapatra, 2014 .

ACY-241, a Novel, HDAC6 Selective Inhibitor: Synergy with Immunomodulatory (IMiD®) Drugs in Multiple Myeloma (MM) Cells and Early Clinical Results (ACE-MM-200 Study)

P. Richardson, N. Raje, N. Trede, 2015 .

Abstract 5380: Selective HDAC inhibition by ricolinostat (ACY-1215) or ACY-241 synergizes with IMiD® immunomodulatory drugs in Multiple Myeloma (MM) and Mantle Cell Lymphoma (MCL) cells

Simon S. Jones, S. Quayle, D. Tamang, 2015 .

microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma.

Yonghong Xiao, David L Rimm, James J Collins, 2012, Cancer discovery.

miR-34a as a novel regulator of TGFβ signaling in GBM

J. Collins, L. Chin, W. Wiedemeyer, 2012 .

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia

K. Bhalla, J. Shearstone, D. Shrieve, 2017, Leukemia.

PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas.

Yonghong Xiao, Lynda Chin, Jian Hu, 2010, Cancer cell.

Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM

Yonghong Xiao, Joseph Rosenbluh, Ian F. Dunn, 2010, Proceedings of the National Academy of Sciences.

Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers

F. Bertucci, D. Birnbaum, W. Woodward, 2017, Breast Cancer Research.

Somatic Mutations of PIK3R1 Promote Gliomagenesis

Li Ding, Keith L. Ligon, Lynda Chin, 2012, PloS one.

Somatic Mutations of PIK 3 R 1 Promote Gliomagenesis

R. Wilson, L. Chin, G. Mills, 2012 .

NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model.

P. Hammerman, Kwok-Kin Wong, J. Bradner, 2018, Cancer research.

CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies

K. Pienta, S. Almo, P. Kiener, 2020, Clinical Cancer Research.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

J. Shearstone, Pengyu Huang, Simon S. Jones, 2017, PloS one.

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer.

Guocheng Yuan, P. Hammerman, Kwok-Kin Wong, 2017, Cancer discovery.

In Vitro and In Vivo Interactions between the HDAC6 Inhibitor Ricolinostat (ACY1215) and the Irreversible Proteasome Inhibitor Carfilzomib in Non-Hodgkin Lymphoma Cells

S. Grant, Simon S. Jones, S. Quayle, 2014, Molecular Cancer Therapeutics.

Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.

J. Pinilla-Ibarz, Simon S. Jones, E. Sotomayor, 2018, Blood advances.

Novel expressed sequences identified in a model of androgen independent prostate cancer

Steven J. M. Jones, Allen D. Delaney, J. Schein, 2007, BMC Genomics.

Identification and characterization of genes associated with the hormonal progression of prostate cancer

S. Quayle, 2006 .

Integrative functional genomics identifies RINT1 as a novel GBM oncogene

P. Tamayo, L. Chin, W. Hahn, 2012, Neuro-oncology.

14-3-3 sigma increases the transcriptional activity of the androgen receptor in the absence of androgens.

M. Sadar, S. Quayle, 2007, Cancer letters.

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models

Ralph Mazitschek, Pengyu Huang, Simon S. Jones, 2015, Oncotarget.

A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells.

M. Sadar, S. Quayle, 2006, Genomics.

Inhibition of HSP90 by AT13387 Delays the Emergence of Resistance to BRAF Inhibitors and Overcomes Resistance to Dual BRAF and MEK Inhibition in Melanoma Models

Kristina M. Ilieva, V. Petrenko, V. Sondak, 2014, Molecular Cancer Therapeutics.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia

J. Shearstone, Pengyu Huang, Simon S. Jones, 2017, PloS one.

Erratum to: HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers

F. Bertucci, D. Birnbaum, W. Woodward, 2017, Breast Cancer Research.